ESMO: Roche wants oral SERD to benefit ‘all comers’
Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% for a…
Roche’s Tecentriq Cuts Death Risk 41% in ctDNA‑guided MIBC
Roche (OTCQX: RHHBY) reported positive phase III IMvigor011 results for Tecentriq (atezolizumab) as…
Roche oral SERD giredestrant boosts iDFS in early breast cancer
Roche (OTCQX: RHHBY) reported positive Phase III results from the lidERA trial of…